Foghorn Therapeutics
Novel BRG1/BRM Inhibitor in Metastatic Uveal Melanoma Shows Safety and Preliminary Efficacy
SG Tylor
Source – Foghorn Therapeutics Foghorn Therapeutics has highlighted the safety and tolerability of FHD-286 in metastatic uveal melanoma (mUM) through ...